Dr. Volker RUDAT is the Consultant of the Department of Radiation Oncology at Jiahui International Cancer Center, and Professor of Radiation Oncology at the University Hospital Hamburg (UKE), Germany. 

He received his scientific and clinical education at the German Cancer Research Center (dkfz) and University of Heidelberg, Germany. In 2001, he was appointed Professor and Vice Director of the Department of Radiation Oncology of the University Hospital Hamburg (UKE) and in 2006, Director of the Department of Radiation Oncology of the St. Josef University Hospital, Bochum, Germany. Dr. Rudat followed an invitation to Al Khobar, Saudi Arabia, where he and his team established a large Oncology Center. 

Dr. Rudat has performed many clinical and radiobiological studies which are reflected in more than 100 international scientific publications. He contributed scientifically to the development of concomitant radiochemotherapy, intensity-modulated radiotherapy (IMRT), and image-guided radiotherapy (IGRT). Dr. Rudat served as a principal investigator of a German prospective multicenter study establishing larynx function preserving therapy in Germany. Apart from the radiotherapy and radiochemotherapy of head and neck cancer, his clinical and scientific interest focuses on the radiotherapy of breast cancer, prostate cancer, lung cancer, rectal cancer, and other malignant tumors and benign conditions.

*Scientific publications Dr. Volker RUDAT

Dr. Vicky QI is the Associate Chief Physician and an oncologist at Jiahui International Cancer Center. Dr. QI specializes in the diagnosis and treatment of malignant solid tumors, with expertise in comprehensive medical oncology care for lung cancer, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, bile duct cancer, gallbladder cancer, pancreatic cancer, esophageal cancer, gynecological tumors, and head and neck tumors. She is also skilled in the symptom management of cancer patients. Particularly in lung cancer, Dr. Qi has extensive clinical experience in advanced diagnostic techniques, including bronchoscopy, CT-guided lung biopsy. Additionally, she is proficient in cancer genetic screening, cancer pain management, nutritional support for cancer patients, palliative care, and whole-course management of cancer patients, and is able to give humanistic and psychological care to cancer patients and their family members.
Dr. Qi graduated from Shanghai Jiaotong University School of Medicine in 2012 with master’s degree in Respiratory Medicine, and earned her Ph.D. in Oncology in 2017 from Tongji University School of Medicine. During 2015 and 2016, she worked at M.D. Anderson Cancer Center as a visiting scientist. Before joining Jiahui Health, Dr. Qi served as an Associate Chief Physician in the Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University. Dr. Qi specializes in diagnosis and treatment of solid tumor, especially lung cancer. She also performed the operation of bronchoscopy and CT-guided transthoracic percutaneous fine needle aspiration and core biopsy.
As for scientific research, Dr. Qi has participated in several international and domestic multi-center clinical trials for anti-cancer drugs. She has presided over youth fund of national natural science foundation of China (NSFC) and has been involved in the research of drug resistance in lung cancer. As the first author, she has published more than 10 peer-reviewed papers in SCI Journals.

Dr. WANG Bin serves as a radiation oncologist of Jiahui International Cancer Center. Dr. Wang obtained the bachelor degree of Clinical Medicine from Zhengzhou University School of Medicine in 1999, and then he received the master degree in medical oncology and Ph.D. in pathology at Shanghai Secondary Millitary University. Before joining Jiahui Health, he served as attending physician in the Center of Clinical Oncology, Shenzhen Hospital, Hong Kong University and Department of Radiation at a private cancer center in Shanghai. In 2018, he visited the Cancer Center of Queen Mary Hospital, Hong Kong University and Pamela Youde Nethersole Eastern Hospital. Being a radiation oncologist for more than ten years, he specializes in conventional radiation therapy and stereotactic radiotherapy of various tumors, especially the treatment of gastrointestinal, breast, and head & neck cancers. In addition, he also pays close attention to the cardiac toxicity during breast cancer radiotherapy.

Dr. Wang joined as sub-investigators in a global multi-center clinical trials for liver cancer radiotherapy and a HCC basic research supported by National Natural Science Foundation of China.

He had several academic publications. He had participated in the translation of the English version of Proton Therapy by MDACC and Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy by Nancy Y. Lee.
Dr. Wang is a current member of Chinese Society of Clinical Oncology (CSCO).

HU Chaosu, M.D., is a Professor, Chief Physician, and Doctoral Supervisor. He currently serves as the Director of the Nasopharyngeal Carcinoma Diagnosis and Treatment Center at Fudan University and is the Chief Expert in Nasopharyngeal Carcinoma.

Professor HU is a leading authority in the field of radiotherapy for head and neck tumors in China, with over 30 years clinical expertise in precision radiotherapy, comprehensive treatment, immunotherapy, and targeted therapy for nasopharyngeal carcinoma.

He holds several prestigious positions, including:
-Honorary Chairman of the Nasopharyngeal Carcinoma Professional Committee of the Chinese Anti-Cancer Association
-Chairman of the Nasopharyngeal Carcinoma Quality Control Expert Committee of the National Cancer Center
-Standing Committee Member of the Nasopharyngeal Carcinoma Professional Committee of the Chinese Society of Clinical Oncology (CSCO)
-Chairman of the Head and Neck Tumor Professional Committee of CSCO
-Standing Committee Member of the Head and Neck Tumor Professional Committee of the Chinese Anti-Cancer Association
-Standing Committee Member of the Neuro-Oncology Professional Committee of the Chinese Anti-Cancer Association
-Honorary Chairman of the Radiation Oncology Committee of the Shanghai Medical Association
-Honorary Chairman of the Nasopharyngeal Carcinoma Professional Committee of the Shanghai Anti-Cancer Association

Additionally, he serves as an editorial board member for several academic journals, including Chinese Journal of Radiation Oncology, Cancer, and China Oncology, and is a peer reviewer for multiple international journals.

Dr. XUAN Linli is currently Chief of Medical Oncology at Jiahui International Cancer Center (JICC). With over 30 years of experience in cancer research and clinical practice, Dr. XUAN possesses extensive expertise in diagnosis and treatment of hematologic and oncologic illness, including cancer risk assessment and reduction.

 
After 6 years of study in Shanghai Medical University, Dr. XUAN furthered her clinical training in the Hematology Division of the Internal Medicine Department at Huashan Hospital Fudan University, under the guidance of Professor DING Xunjie, one of the founding figures of the Hematology Department at Huashan Hospital and a key authority in hematology nationwide. Then in the US, she spent an additional 6 years in residency and fellowship training, including specialization in medical oncology and hematology at the University Hospitals, Case Western Reserve University in Cleveland Ohio. Before joining Jiahui Health, Dr. XUAN practiced medical oncology and hematology in the U.S. for over two decades. She obtained certifications from the American Board of Internal Medicine (ABIM) in Internal Medicine, Medical Oncology, and Hematology. Dr. XUAN is also a member of the American Society of Clinical Oncology (ASCO).

 
With a solid academic foundation, systematic training in both China and the U.S., and years of clinical experience in patient care, Dr. XUAN is well-versed in internationally advanced technologies for cancer prevention, diagnosis, and treatment. She is skilled in managing a variety of oncological and hematological diseases. She is detail-oriented and excels in communication with patients and their families. She firmly believes that cancer treatment planning should involve collaboration between patients, families and other disciplines. Additionally, she prioritizes patients' quality of life and is adept at alleviating suffering through standardized, internationally recognized personalized treatment plans and symptom management.

 
Dr. XUAN’s areas of expertise in hematology and oncology treatment include but not limited to:
-Diagnosis and treatment of solid tumors, particularly all stages of breast cancer, advanced gynecological malignancies, advanced prostate cancer and other urological cancer, colorectal cancer, esophageal and stomach cancer, lung cancer, skin cancers especially melanoma, etc.
-Diagnosis and treatment of hematologic malignancies, especially multiple myeloma and lymphoma, chronic lymphocytic leukemia, myeloproliferative neoplasms.
-Diagnosis and treatment of other hematologic conditions, including anticoagulation therapy, platelet disorder, myelodysplastic syndromes and all causes of anemia.
-Cancer genetics, including cancer risk assessment and risk reduction,
-Palliative care, including pain management and supportive therapy.

Dr. ZHU Lifei is currently a multi-site oncologist at Jiahui International Cancer Center and Vice-Chief Physician of the Oncology Department of Shanghai General Hospital affiliated with Shanghai Jiao Tong University School of Medicine. Dr. ZHU serves as a member of the Lymphoma Expert Committee, Lung Cancer Molecular Targeted Therapy and Immunotherapy Expert Committee, and Cancer Rehabilitation and Palliative Care Expert Committee of Shanghai Anti-Cancer Association. She is also actively involved as a member of the China Soong Ching Ling Foundation.

Dr. ZHU began her studies at Shanghai Second Medical University and conducted research in Mental Health at the Graduate School of Tongji University from 2004 to 2006.

With over a 30 years of experience in medical oncology, Dr. ZHU specializes in the treatment of solid tumors, with a particular focus on breast, lung, and gastrointestinal cancers. She is highly skilled in chemotherapy, targeted therapy, and endocrine therapy, especially in the treatment of breast cancer.

HAO Siguo, MD, PhD, is currently a multi-site physician in the Department of Hematology at Jiahui International Cancer Center and director of the Department of Hematology at Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine. He also serves as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor.

Dr. HAO graduated from Shanghai Second Medical University and Shanghai Institute of Hematology with a PhD in Hematology in 2003. In 2000, he was a senior visiting fellow of Hematopoietic Stem Cell Transplantation (HSCT) at the Haematology Centre of Singapore General Hospital. From 2004 to 2007, he conducted postdoctoral research in tumor immunotherapy in Canada.

Dr. HAO has almost 40 years of medical practicing experience. He specializes in the treatment of difficult and complicated hematological diseases, such as acute/chronic leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), aplastic anemia, and anemia, thrombocytopenia caused by various reasons. In addition, he is also an experienced expert in autologous and allogeneic hematopoietic stem cell transplantation (including haploidentical and cord blood transplantation). The Hematology Department of Xinhua Hospital, which he leads, is the only department in Shanghai that performs umbilical cord blood transplantation to treat adult malignant blood tumors. Dr. HAO conducted early clinical research on CAR-T cell therapy for relapsed/refractory lymphoma and multiple myeloma in China, and he has communicated his research results in international conferences many times. And also Dr. HAO has accumulated rich clinical experiences in CAR-T therapy.

Dr. HAO serves as the Vice Chairman of the 10th and 11th Shanghai Hematology Society of Chinese Medical Association, the Vice Chairman of Hematology and Oncology Branch of Shanghai Anti-Cancer Association, the member of Hematology Branch of Chinese Geriatrics Society, the member of Cord Blood Application Committee of Chinese Maternal and Child Health Association, the Vice President of Shanghai Hematopoietic Stem Cell Transplantation Alliance, the Standing Committee member of Hematology Branch of Shanghai Traditional Chinese and Western Medicine Association, the member of Expert Committee of Chinese Stem Cell Bank, the Deputy Director of Shanghai Institute of Hematology, and the member of Hematology Branch of Shanghai Immunology Society. He has undertaken and completed several provincial and ministerial scientific research projects including projects funded by National Natural Science Foundation. Dr. HAO has published more than 100 academic papers, including more than 50 SCI papers. He has presided over 4 National Natural Science Foundation projects. He has also presided several research projects of Shanghai Science and Technology Commission, Health Commission and Shanghai Shenkang Hospital Development Center. Dr. HAO also has been in charge of multiple clinical research projects. He chaired the BCMA CAR-T cell therapy for R/R multiple myeloma program, which has been communicated in several oral presentations at international congresses such as IMWG, ASH, etc., and the results of his research have also been published in the journal Haematologica 2023.

Dr. XUE Peng is the Associate Chief Physician and the Assistant to Chief of Medical Oncology at Jiahui International Cancer Center. Dr. XUE specializes in the comprehensive management of malignant solid tumors, utilizing advanced treatment modalities such as chemotherapy, targeted therapy, immunotherapy, and PORT implantation. His expertise covers a wide range of common solid tumors, including gastrointestinal, pancreatic, breast, lung, genitourinary, and gynecological cancers, as well as rare tumor types. Additionally, he places a strong emphasis on the symptomatic care of cancer patients, with extensive clinical experience in managing cancer-related pain, preventing and treating chemotherapy-induced nausea and vomiting (CINV), and providing palliative care.
Dr. XUE graduated from Shanghai Second Medical University with Bachelor degree in 2000. He then spent three years conducting research at the State Key Laboratory of Oncogenes and Related Genes at Shanghai Cancer Institute (2000–2003). In 2006, he achieved Master degree in Medical Oncology at Shanghai Jiaotong University School of Medicine. Before joining Jiahui Health, Dr. XUE had worked for many years in the Medical Oncology Department of Shanghai General Hospital since 2006, and obtained his Ph.D. degree in Medical Oncology during the work. Dr. XUE was awarded the Sasagawa Fellowship for academic funding and participated in pancreatic cancer research as a visiting scholar in Kyoto University Hospital in Japan from 2012 to 2013. He has published several peer-reviewed papers in the field of chemotherapy for pancreatic cancer patients.
He is currently a member of Chinese Society of Clinical Oncology and Japan-china Medical Association.

Dr. XU Rong serves as an attending physician in medical oncology department of Jiahui International Cancer Center. Dr. Xu got her Bachelor’s Degree in Clinical Medicine in 2003 and Medical Master’s Degree in Hematology in 2007 from Shanghai Jiaotong University School of Medicine. From 2007 to 2017, Dr. Xu worked in the First People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Before joining Jiahui, Dr. Xu was in charge of the HSCT unit in a hematology hospital, specializing in autologous and allogeneic hematopoietic stem cell transplantation and CAR-T cell therapy for relapsed and refractory hematologic tumors. She is adept at managing complications in allogeneic hematopoietic stem cell transplantation, treating post allogeneic HSCT problems such as GVHD, infections, primary and secondary graft failure, thrombotic complications, tumor relapse, etc. Dr. Xu also has extensive experience in autologous hematopoietic stem cell transplantation for multiple myeloma and lymphoma, and CAR-T cell therapy including auto-HSCT bridging CAR-T, tandem CAR-T, double-target CAR-T. Dr. Xu has mastered the technology of invasive and non-invasive mechanical ventilation, continuous renal replacement therapy, hemodynamic monitoring, and intensive rehabilitation techniques. Dr. Xu is qualified in internal medicine, critical care medicine and rehabilitation medicine. As for academic field, she has published more than ten Chinese core journal articles and two SCI papers.

Dr. ZHANG Lihua currently serves as the section head of radiation oncology department at Jiahui International Cancer Center. Dr. ZHANG completed her six-year clinical medical program in Japanese at Norman Bethune Health Science Center of Jilin University in 2003. She obtained her clinical master degree from Obstetrics & Gynecology Hospital of Fudan University and PhD degree of Oncology from Fudan University Shanghai Cancer Center. Since 2012, Dr. ZHANG has received extensive training in Internal Medicine and undergone resident standardization training and specialist training in Radiotherapy at Shanghai Sixth People's Hospital. In October 2014, she visited Heidelberg University Medical School in Germany, focusing on intraoperative radiotherapy techniques for breast cancer, pancreatic cancer, and gynecological tumors. With over ten years of experience in radiation oncology department, Dr. ZHANG also serves as a national instructor for resident standardization training and specialist training in radiation oncology.

Dr. ZHANG specializes in the comprehensive treatment of a wide range of cancers through radiotherapy and chemotherapy. Her expertise extends to gynecological tumors, including cervical, vaginal, and endometrial cancers; gastrointestinal tumors such as esophageal, pancreatic, stomach, intestinal, and liver cancers; head and neck tumors like nasopharyngeal, nasal sinus, ear canal, parotid gland, and gliomas; thoracic tumors including lung and thymus cancers; and urological tumors encompassing bladder, kidney, ureteral, and prostate cancers. Furthermore, Dr. ZHANG is adept in treating soft tissue tumors, bone tumors, lymphomas, myelomas, breast cancer, and benign conditions such as synovitis, heterotopic ossification, and keloids with advanced radiotherapy techniques. These techniques include adaptive radiotherapy, intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), intraoperative radiation therapy (IORT), stereotactic body radiotherapy (SBRT), and brachytherapy. She is particularly experienced in using AI-assisted radiotherapy for the treatment of complex, recurrent, and metastatic tumors, and re-irradiation, especially in brachytherapy for gynecological tumors.

Dr. ZHANG has published dozens of articles in Chinese and English, primarily involved in three projects at the directorate and municipal science committee level related to cervical cancer and esophageal cancer. Currently, she is a member of the youth committee of radiotherapy branch of the Shanghai Medical Association, and a member of the youth radiotherapy committee of the Shanghai Anti-Cancer Association.